Ignite Creation Date:
2024-05-05 @ 4:51 PM
Last Modification Date:
2024-10-26 @ 9:25 AM
Study NCT ID:
NCT00328198
Status:
COMPLETED
Last Update Posted:
2014-03-13
First Post:
2006-05-18
Brief Title:
Subcutaneous Alemtuzumab CAMPATH MabCampath in RelapsedRefractory B-Cell Chronic Lymphocytic Leukemia
Sponsor:
Organization:
Sanofi